Tissue decellularization is a well-established technique in tissue engineering to preserve the biochemical complexity of native tissues. However, its application in recreating the tumor stroma for in vitro studies remains limited, with current models often relying on non-specific extracellular matrices that lack the unique characteristics of the tumor microenvironment. Here, we present a novel technology to develop hydrogels from decellularized tumor tissue using a tumor cell culture-derived matrix. This new technology, developed as part of the ERC project ICoMICS, improves the preservation of the composition of the matrix, in contrast to currently available alternatives. Hence, this technology creates a market opportunity to improve the development of hydrogels not only for cancer modeling, but also for a wide range of potential applications in disease modeling and regenerative medicine. In addition, by leveraging our extensive expertise in hydrogel characterization, we will expand our products not only for the production of specific hydrogels, but also for the characterization of all types of hydrogels according to the specific needs of potential users.
Therefore, the main objective of this proof of concept is to assess the potential of this project to evolve into a spin-off company focused on:
- commercializing novel hydrogels for tumor and disease modeling, and
- providing potential customers with a wide range of accessible and thorough characterization methods.
In addition, we aim to assess the market opportunities for both the commercialization of our hydrogel products and the establishment of a specialized characterization service providing in-depth physicochemical analysis of biomaterials for research groups and industry stakeholders.
